This invention belongs to the field of
biomedical technology, specifically disclosing an injectable
embolic agent, its preparation method, and its application. The
embolic agent is a hydrocolloid
system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit
copper ion efflux and promote
intracellular copper accumulation, and interact with Cu 2+ It synergistically induces
copper death in
tumor cells; the shell is a thermosensitive block
copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a
sol-gel transition occurs at physiological temperatures, enabling precise
vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit
hepatocellular carcinoma model, this
embolization agent significantly improved tumor
necrosis rate and reduced
metastasis rate compared to traditional
iodized oil embolization; it also downregulated hypoxia- and
angiogenesis-
related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and
metastasis, and promoted CD8+. + T-
cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.